Search results
Author(s):
Rasha Al-Lamee
,
Christopher Rajkumar
,
Nazli Okumus
Added:
2 years ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA…
View more
Author(s):
Armin Arbab-Zadeh
,
Michelle Graham
,
Hector M Garcia-Garcia
,
et al
Added:
4 months ago
Author(s):
Nello Cambise
,
Angelo Giuseppe Marino
,
Fabio De Benedetto
,
et al
Added:
15 hours ago
Author(s):
Johanna McChord
,
Astrid Hubert
,
Udo Sechtem
,
et al
Added:
1 year ago
Author(s):
Rasha Al-Lamee
,
Michael Foley
Added:
1 year ago
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and…
View more
Author(s):
Matthew J Budoff
Added:
9 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical…
View more
Rodney H Stables
Research Area(s) / Expertise:
Author
Author(s):
Mandeep Mehra
,
Christian Inchaustegui
Added:
2 years ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
View more
Author(s):
Evan A Stein
Added:
1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period…
View more
Author(s):
Gaetano Antonio Lanza
Added:
7 months ago